dc.contributor.author | Popat, S | |
dc.contributor.author | Brustugun, OT | |
dc.contributor.author | Cadranel, J | |
dc.contributor.author | Felip, E | |
dc.contributor.author | Garassino, MC | |
dc.contributor.author | Griesinger, F | |
dc.contributor.author | Helland, Å | |
dc.contributor.author | Hochmair, M | |
dc.contributor.author | Pérol, M | |
dc.contributor.author | Bent-Ennakhil, N | |
dc.contributor.author | Kruhl, C | |
dc.contributor.author | Novello, S | |
dc.date.accessioned | 2021-09-21T13:38:16Z | |
dc.date.available | 2021-09-21T13:38:16Z | |
dc.identifier.citation | Lung cancer (Amsterdam, Netherlands), 2021, 157 pp. 9 - 16 | |
dc.identifier.issn | 0169-5002 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4821 | |
dc.identifier.eissn | 1872-8332 | |
dc.identifier.doi | 10.1016/j.lungcan.2021.05.017 | |
dc.description.abstract | Background The next-generation ALK inhibitor brigatinib is approved for use in patients with ALK inhibitor-naïve ALK-positive advanced NSCLC and in patients previously treated with crizotinib. A phase II trial showed that brigatinib is active in patients with ALK-positive metastatic NSCLC (mNSCLC) who had progressed on prior crizotinib (response rate 56 %, median PFS 16.7 months, median OS 34.1 months). We report final data from the UVEA-Brig study of brigatinib in ALK inhibitor-pretreated ALK-positive mNSCLC in clinical practice.Methods UVEA-Brig was a retrospective chart review of patients treated with brigatinib in Italy, Norway, Spain and the UK in an expanded access program. Adults with ALK-positive mNSCLC, including those with brain lesions, resistant to or intolerant of ≥1 prior ALK inhibitor and ECOG performance status ≤3 were eligible. Patients received brigatinib 180 mg once daily with a 7-day lead-in at 90 mg. The objectives were to describe patient characteristics, clinical disease presentation, treatment regimens used and clinical outcomes.Results Data for 104 patients (male: 43 %; median age: 53 [29-80] years; ECOG performance status 0/1/2/3: 41/41/10/5 %; brain/CNS metastases: 63 %) were analyzed. Patients had received a median of 2 (1-6) lines of systemic therapy prior to brigatinib (37.5 % received ≥3) and a median of 1 (1-5) lines of prior ALK inhibitor-containing therapy (crizotinib 83.6 %; ceritinib 50.0 %; alectinib 6.7 %; lorlatinib 4.8 %). At the time of analysis, 77 patients had discontinued brigatinib. Overall, the response rate was 39.8 %, median PFS was 11.3 (95 % CI:8.6-12.9) months and median OS was 23.3 (95 % CI: 16.0-NR) months. Four patients discontinued brigatinib treatment due to adverse events. 53 patients received systemic therapy after brigatinib, 42 with an ALK inhibitor (lorlatinib, n = 34).Conclusions These real-world data indicate the activity and tolerability of brigatinib in patients with ALK-positive mNSCLC who were more heavily pretreated than patients included in clinical trials. | |
dc.format | Print-Electronic | |
dc.format.extent | 9 - 16 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Lung Neoplasms | |
dc.subject | Organophosphorus Compounds | |
dc.subject | Pyrimidines | |
dc.subject | Protein Kinase Inhibitors | |
dc.subject | Treatment Outcome | |
dc.subject | Retrospective Studies | |
dc.subject | Adult | |
dc.subject | Middle Aged | |
dc.subject | Italy | |
dc.subject | Norway | |
dc.subject | Spain | |
dc.subject | Male | |
dc.subject | Anaplastic Lymphoma Kinase | |
dc.title | Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-05-12 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.lungcan.2021.05.017 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Lung cancer (Amsterdam, Netherlands) | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 157 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Thoracic Oncology | |
icr.researchteam | Thoracic Oncology | |
dc.contributor.icrauthor | Popat, Sanjay | |